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The anaerobic bacterium Clostridium difﬁcile is a
major nosocomial pathogen, the most commonly
diagnosed cause of infectious hospital diarrhoea.
There is now evidence that C. difﬁcile is also
causing diarrhoea in the community, both as a
result of exposure to hospitals and de novo. The
clinical spectrum of cases presenting with C. dif-
ﬁcile disease can be wide, ranging from asymp-
tomatic carriage, to mild self-limiting diarrhoea,
and more severe pseudo-membranous colitis.
Antimicrobial exposure remains the most signi-
ﬁcant risk-factor for acquiring C. difﬁcile. There is
great concern worldwide following the recent
emergence in Canada, the USA, and now Europe,
of a new highly virulent strain of C. difﬁcile (called
PCR ribotype 027 in Europe and NAP1 in the
USA). Rates of detection of C. difﬁcile have risen
dramatically, C. difﬁcile disease has been more
severe, and attributable mortality is high.
While C. difﬁcile disease was once viewed by
some as more of an annoyance than a serious
hospital-acquired infection, many hospitals are
now moving rapidly towards implementing a
range of infection control measures to stem the
tide. The value of sensible policies regarding
antibiotic use, as well as good infection control
procedures implemented by responsible per-
sonnel, cannot be over-emphasised. Antibiotic
restriction can be effective in reducing C. difﬁcile-
associated diarrhoea. In response to the outbreak
in Canada, the Quebec government provided
Can$30 million to hospitals in the province to
buy additional equipment and hire infection con-
trol staff. In the long term, such initiatives are
likely to impact not only on C. difﬁcile-associated
diarrhoea but also on methicillin-resistant Staphy-
lococcus aureus, vancomycin-resistant enterococci
and other organisms that pose a challenge to
infection control programmes.
Money alone will not solve this problem. What
is also required is good-quality research in the
ﬁelds of hospital epidemiology and infection
control, to allow formulation of policy and
practice. Such research should comply with the
principles espoused in the ORION statement. In
this supplement to Clinical Microbiology and Infec-
tion, the current state of knowledge about C. dif-
ﬁcile as a cause of diarrhoeal illness is reviewed so
that healthcare institutions and jurisdictions can
develop evidence-based guidelines to limit the
spread of C. difﬁcile.
Corresponding author and reprint requests: T. V. Riley,
Microbiology & Immunology, The University of Western
Australia and Division of Microbiology and Infectious Disease,
PathWest Laboratory Medicine, Queen Elizabeth II Medical
Centre, Nedlands 6009, Western Australia, Australia
E-mail: triley@cyllene.uwa.edu.au
TVR and PH conﬁrm that they have no conﬂicts of interest
with respect to this publication.
 2008 The Authors
Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 5), 1
